Global Companion Diagnostics Market 2014-2018

Reportstack Announces the Publication of its Research Report - Global Companion Diagnostics Market 2014-2018. The following companies are the key players in Global Companion Diagnostics Market: Abbott Laboratories, Agilent Technologies Inc., bioMérieux SA, Qiagen N.V., Roche Holding AG, 20/20 Genesystems Inc. , A & G Pharmaceutical Inc., AccuTheranostics Inc., Alacris Theranostics GmbH, AutoGenomics Inc., Biogenex Laboratories Inc., LeicaBiosystems GmbH, Life Technologies Inc., Luminex Corp., pHLOGISTIX LLC, Spartan Bioscience Inc., TheraDiag S.A., Theranostics Health Inc., Ventana Medical Systems Inc.

“One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period.”

According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease.

Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit